Highlights
- Imugene has secured a patent for its licenced oncolytic virotherapy in the United States.
- Oncolytic virotherapy CF33 comprises CHECKVacc and VAXINIA.
- The patent protects the composition and usage methodology of the oncolytic virotherapy to 2037.
Imugene Limited (ASX: IMU), an Australian clinical-stage immune-oncology company, has informed about receiving a notice of allowance from the USPTO (US Patent and Trademark Office). The latest development of securing a US patent extends protection to the company’s oncolytic virotherapy CF33.
Oncolytic virotherapy CF33 comprises CHECKVacc (CF33-hNIS-antiPDL1) and VAXINIA (CF33-hNIS).
Share price performance of Imugene
Following the update, the share price of Imugene jumped to AU$0.10 per share, 9.68% higher at the time of writing on 19 July 2022. The company has a market cap of over AU$597 million.
About the patent
The title of the patent is - “CHIMERIC POXVIRUS COMPOSITION AND USES THEREOF”, and the inventors are Yuman Fong and Nanhai Chen from the City of Hope. The patent protects the composition and usage methodology of the oncolytic virotherapy to 2037.
About oncolytic virotherapy CF33
CF33 is a chimeric vaccinia poxvirus, invented by Professor Yuman Fong.
The design of oncolytic viruses (OVs) activates the immune system against cancer cells and selectively kills tumour cells. OVs have the potential to enhance clinical responses and survival, says the company.